Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Sputnik M is a new member of the Sputnik vaccines family
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Panacea Biotec receives LoA from CMSS
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
Subscribe To Our Newsletter & Stay Updated
